Presentation (CTI)

OBJECTIVES: While belamaf as a single-agent therapy for R/R MM was withdrawn from the US market in early 2023, recent results from the DREAMM-7 phase III trial support improved progression-free survival for patients with R/R MM who received B-Vd versus daratumumab, bortezomib, and dexamethasone (D-Vd) after at least one prior line of therapy (LOT). As providers’ receptivity to a potential reentry of belamaf to the US market remains unknown, we conducted qualitative research to understand providers’ perspectives on the DREAMM-7 results, potential adoption of B-Vd, and toxicity-related concerns should B-Vd receive approval.
METHODS: Survey questions on the DREAMM-7 results were administered to US-based oncologists at two in-person forums in July and September 2024 (N=96). Responses were captured via audience response system technology, and providers were not required to answer every question. Data from both forums were pooled and analyzed descriptively.
RESULTS: Participating providers predominantly practiced in community settings (79.2%) and had a median 19.5 years of clinical experience post-residency. The majority of providers (60.6%) had not prescribed belamaf prior to its withdrawal, with 27.7% having prescribed it for 1-10% of patients with R/R MM. After reviewing the DREAMM-7 trial results, the majority of providers were receptive to prescribing B-Vd for R/R MM patients with ≥1 prior LOTs (59.1% somewhat or very likely), with greater preference for use in 4L or later. Providers cited the high number of grade ≥3 ocular adverse events (64.5%) and intense monitoring required for management of ocular adverse events (53.8%) as the greatest potential deterrents to prescribing B-Vd.
CONCLUSIONS: Overall, providers were receptive to prescribing B-Vd for patients with R/R MM in later LOTs, should belamaf re-enter the US market. Nevertheless, treatment management strategies for ocular events remain needed for broader adoption, including methods for increasing availability and coordination with ophthalmologists in the community settings.